Wilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor snf96.2 cell line

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Parenti, Rosalba ^a   Cardile, Venera ^a   Graziano, Adriana Carol Eleonora ^a   Parenti, Carmela ^a   Venuti, Assunta ^b   Bertuccio, Maria Paola ^b   Lo Furno, Debora ^a   Magro, Gaetano ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b Medical Oncology Unit   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN KINASE B; SMALL INTERFERING RNA; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING; WILMS TUMOR GENE 1; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; NEURILEMOMA; PATHOLOGY;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEURILEMMOMA; RNA INTERFERENCE; WT1 PROTEINS;

EID: 84916205564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114333     Document Type: Article

References (83)

1. Weiss SW, Goldblum JR (2008) Enzinger and Weiss's Soft Tissue Tumors, 5th Edition. Edited by Mosby-Elsevier. 903-925.
2. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, et al. (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39: 311-4.
3. Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN (2008) Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97(4): 340-9.
4. Katz D, Lazar A, Lev D (2009) Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med 19; 11: e30.
5. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, et al. (2010) Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol 136(12): 1869-80.
6. Upadhyaya M (2011) Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci 16: 937-951.
7. Carroll SL (2012) Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol 123: 321-348.
8. Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, et al. (2013) NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Int J Oncol 42(2): 657-66.
9. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, et al. (1990) Isolation and characterization of a zinc finger polypeptidegene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-20.
10. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, et al. (1990) Homozygous deletion in Wilms' tumors of a zinc-finger gene identified by chromosome jumping. Nature (Lond) 343: 774-8.
11. Lee SB, Haber DA (2001) Wilms tumor and the WT1 gene. Exp Cell Res 264 (1): 74-99.
12. Ellisen LW (2002) Regulation of gene expression by WT1 in development and tumorigenesis. Int J Hematol 76: 110-116.
13. Hohenstein P, Hastie ND (2006) The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No. 2: R196-R201.
14. Menke AL, van der Eb AJ, Jochemsen AG (1998) The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int Rev Cytol; 181: 151-212.
15. Hartkamp J, Roberts SG (2008) The role of the Wilms' tumour-suppressorprotein WT1 in apoptosis. Biochem Soc Trans 36: 629-31.
16. Huff V (2011) Wilms' tumours: about tumour suppressor genes, anoncogene and a chameleon gene. Nat Rev Cancer 11: 111-21.
17. Parenti R, Perris R, Vecchio GM, Salvatorelli L, Torrisi A, et al. (2013) Immunohistochemical expression of Wilms' tumor protein (WT1) in developing human epithelial and mesenchymal tissues. Acta Histochem. Jan; 115(1): 70-5.
18. Parenti R, Puzzo L, Vecchio GM, Gravina L, Salvatorelli L, et al. (2014) Immunolocalization of Wilms' Tumor protein (WT1) in developing human peripheral sympathetic and gastroenteric nervous system. Acta Histochem 116(1): 48-54.
19. Scharnhorst V, van der Eb AJ, Jochemsen AG (2001) WT1 proteins: functions in growth and differentiation. Gene. 273(2): 141-61.
20. Yang L, Han Y, Suarez Saiz F, Minden MD (2007) A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876.
21. Roberts SG (2005) Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 15(5): 542-7.
22. Wagner N, Wagner KD, Schley G, Coupland SE, Heimann H, et al. (2002) The Wilms' tumor suppressor WT1 is associated with the differentiation of retinoblastoma cells. Cell Growth Differ 13: 297-305.
23. Wagner N, Wagner KD, Hammes A, Kirschner KM, Vidal VP, et al. (2005) A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system. Development 132(6): 1327-36.
24. Lovell MA, Xie C, Xiong S, Markesbery WR (2003) Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res 983: 84-96.
25. Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, et al. (2010) Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platformanalysis. Hum Mol Genet 19: 1438-52.
26. Sugiyama H (2010) WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 40(5): 377-87.
27. Wagner KD, Wagner N, Schedl A (2003) The complex life of WT1. J Cell Sci 116: 1653-1658.
28. Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, et al. (2003) Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94(3): 271-6.
29. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, et al. (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-14.
30. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, et al. (2002) Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100(3): 297-303.
31. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, et al. (2001) Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61(3): 921-5.
32. Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, et al. (2004) WT1 is a tumorassociated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 109(3): 385-92.
33. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, et al. (2004) Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95(7): 583-7.
34. Amini Nik S, Hohenstein P, Jadidizadeh A, Van Dam K, Bastidas A, et al. (2005) Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Int J Cancer 114(2): 202-8.
35. Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6(5): 405-9.
36. Chen Z (2001) The possible role and application of WT1 in human leukemia. Int J Hematol 73(1): 39-46.
37. Carpentieri DF, Nichols K, Chou PM, Matthews M, Pawel B, et al. (2002) The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors. Mod Pathol 15: 1080-6.
38. Salvatorelli L, Bisceglia M, Vecchio G, Parenti R, Galliani C, et al. (2011) A comparative immunohistochemical study of oncofetalcytoplasmic WT1 expression in human fetal, adult and neoplastic skeletal muscle. Pathologica 103: 186.
39. Oue T, Uehara S, Yamanaka H, Takama Y, Oji Y, et al. (2011) Expression of Wilms tumor 1 gene in a variety of pediatric tumors. J Pediatr Surg 46: 2233-8.
40. Magro G, Longo F, Salvatorelli L, Vecchio GM, Parenti R (2014) Wilms' tumor protein (WT1) in mammary myofibroblastoma: An immunohistochemical study. Acta Histochem 116(5): 905-10.
41. Wagner N, Panelos J, Massi D, Wagner KD (2008) The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 455(5): 839-47.
42. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, et al. (2004) Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95: 822-827.
43. Wang J, Oue T, Uehara S, Yamanaka H, Oji Y, et al. (2011) The role of WT1 gene in neuroblastoma. J Pediatr Surg 46: 326-31.
44. Mahzouni P, Meghdadi Z (2013) WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index. Adv Biomed Res 14; 2: 33.
45. Schittenhelm J, Thiericke J, Nagel C, Meyermann R, Beschorner R (2010) WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy. Cancer Biomark 7(2): 73-7.
46. Inagaki T, Fukuda T, Ohta A, Hano H (2011) Oncogenic role for WT1 in peripheral nerve sheath tumors. Jikeikai Med J 58: 95-102.
47. Singh A, Mishra AK, Ylaya K, Hewitt SM, Sharma KC, et al. (2012) Wilms tumor-1, claudin-1 and ezrin are useful immunohistochemical markers that help to distinguish schwannoma from fibroblastic meningioma. Pathol Oncol Res. 18(2): 383-9.
48. Navakanit R, Graidist P, Leeanansaksiri W, Dechsukum C (2007) Growth inhibition of breast cancer cell line MCF-7 by siRNA silencing of Wilms tumor 1 gene. J Med Assoc Thai. 90(11): 2416-21.
49. Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM (2002) Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 295(4): 784-90.
50. Wang X, Gao P, Lin F, Long M, Weng Y, et al. (2013) Wilms' tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway. Cancer Cell Int 13(1): 114.
51. Zapata-Benavides P, Manilla-Muñoz E, Zamora-Avila DE, Saavedra-Alonso S, Franco-Molina MA, et al. (2012) WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncol Lett 3(4): 751-755.
52. Zamora-Avila DE, Franco-Molina MA, Trejo-Avila LM, Rodríguez-Padilla C, Reséndez-Pérez D, et al. (2007) RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res 17: 341-348.
53. Clark AJ, Ware JL, Chen MY, Graf MR, Van Meter TE, et al. (2010) Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. J Neurosurg 112(1): 18-25.
54. Chen MY, Clark AJ, Chan DC, Ware JL, Holt SE, et al. (2011) Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol 103(1): 87-102.
55. Tatsumi N, Oji Y, Tsuji N, Tsuda A, Higashio M, et al. (2008) Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol. 32(3): 701-11.
56. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, Saavedra-Alonso S, Trejo-Avila LM, et al. (2009) WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther 16(12): 892-9.
57. Fieber LA, González DM, Wallace MR, Muir D (2003). Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiol Dis 13(2): 136-46.
58. Li Y, Rao PK, Wen R, Song Y, Muir D, et al. (2004) Notch and Schwann cell transformation. Oncogene 23(5): 1146-52.
59. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 24(7): 366-76.
60. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-79.
61. Wilm B, Ladomery MR (2010) A report of the first international WT1 meeting, University of Manchester UK, 2008. Int J Mol Epidemiol Genet 1(1): 76-82.
62. Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND (2004) The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 13(4): 463-71.
63. Roberts SG (2006) The modulation of WTI transcription function by cofactors. Biochem Soc Symp (73): 191-201.
64. Dudnakova T, Spraggon L, Slight J, Hastie N (2010) Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene 29(7): 1085-92.
65. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, et al. (2006) Wilms' tumor gene WT117AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97(4): 259-70.
66. Rong Y, Cheng L, Ning H, Zou J, Zhang Y, et al. (2006) Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res 66(16): 8049-57.
67. Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33(2): 173-80.
68. Loeb DM (2006) WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle 5(12): 1249-53.
69. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, et al. (1996) A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12: 1005-1014.
70. Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD, et al. (2002) Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 277(22): 19627-32.
71. Tuna M, Chavez-Reyes A, Tari AM (2005) HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 24: 1648-1652.
72. Lee PR, Cohen JE, Tendi EA, Farrer R, DE Vries GH, et al. (2004) Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells. Neuron Glia Biol 1(2): 135-47.
73. Xu C, Wu C, Xia Y, Zhong Z, Liu X, et al. (2013) WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo. PLoS One 8(8): e68837.
74. He YY, Council SE, Feng L, Chignell CF (2008) UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/cyclin D1 pathways in keratinocytes. Cancer Research 68(10): 3752-3758.
75. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573): 1655-7.
76. Ouyang W, Li J, Zhang D, Jiang BH, Huang C (2007) PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J Cell Biochem 101(4): 969-78.
77. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG (2004) Cyclin D1: normal and abnormal functions. Endocrinology 145 (12): 5439-5447.
78. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25: 1620-1628.
79. Liu XW, Gong LJ, Guo LY, Katagiri Y, Jiang H, et al. (2001) The Wilms' tumor gene product WT1 mediates the down- regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem 276: 5068-5073.
80. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, et al. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102: 8573-8.
81. Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, et al. (2008) Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7: 1237-45.
82. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, et al. (2009) Dual targeting of AKTand mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 8(5): 1157-68.
83. Johanssonn A-C, Steen H, Öllinger K, Roberg K (2003) Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporine. Cell Death and Differentiation 10: 1253-59.